Bair Teresa Brophy 4

What Happened
Teresa Bair, Chief Legal Officer of Kura Oncology (KURA), sold 2,256 shares on May 18, 2026 in an open‑market transaction. The shares were sold at a weighted average price of $9.38 per share (range $9.28–$9.49), for total proceeds of approximately $21,160. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: May 18, 2026; filed May 20, 2026 (appears timely under Form 4 rules).
• Price: weighted average $9.38; individual trades ranged $9.28–$9.49 (reported as multiple trades).
• Total shares sold: 2,256; total proceeds ≈ $21,160.
• Shares acquired shortly before sale: the 2,256 shares were acquired on May 17, 2026 under the issuer's Employee Stock Purchase Plan (ESPP) (footnote).
• Plan/authorization: sale was executed pursuant to a Rule 10b5‑1 trading plan adopted Sept 4, 2025.
• Detailed per‑trade price/quantity breakdown available upon request per the filing (footnote).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context
A 10b5‑1 plan indicates the sale was pre‑scheduled, which is common for executives to manage routine dispositions and reduces inference about immediate insider sentiment. Selling shares that were just acquired via an ESPP is also common for liquidity or tax reasons. This filing is factual disclosure of the sale only and does not explain the insider’s motives.